19 June 2013
Keywords: enrollment, well, track, ph, iii, tlt, trial
Article | 28 January 2008
Swiss biotechnology firm Arpida has initiated patient screening for enrolment into a pivotal Phase III study of its TLT treatment ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 January 2008
18 June 2013
© 2013 thepharmaletter.com